Mixed-methods economic evaluation of the implementation of tobacco treatment programs in National Cancer Institute-designated cancer centers.

Economic evaluation Implementation costs Mixed methods Smoking cessation Tobacco treatment

Journal

Implementation science communications
ISSN: 2662-2211
Titre abrégé: Implement Sci Commun
Pays: England
ID NLM: 101764360

Informations de publication

Date de publication:
09 Apr 2021
Historique:
received: 24 01 2021
accepted: 01 04 2021
entrez: 10 4 2021
pubmed: 11 4 2021
medline: 11 4 2021
Statut: epublish

Résumé

The Cancer Center Cessation Initiative (C3I) was launched in 2017 as a part of the NCI Cancer Moonshot program to assist NCI-designated cancer centers in developing tobacco treatment programs for oncology patients. Participating centers have implemented varied evidence-based programs that fit their institutional resources and needs, offering a wide range of services including in-person and telephone-based counseling, point of care, interactive voice response systems, referral to the quitline, text- and web-based services, and medications. We used a mixed methods comparative case study design to evaluate system-level implementation costs across 15 C3I-funded cancer centers that reported for at least one 6-month period between July 2018 and June 2020. We analyzed operating costs by resource category (e.g., personnel, medications) concurrently with transcripts from semi-structured key-informant interviews conducted during site visits. Personnel salary costs were estimated using Bureau of Labor Statistics wage data adjusted for area and occupation, and non-wage benefits. Qualitative findings provided additional information on intangible resources and contextual factors related to implementation costs. Median total monthly operating costs across funded centers were $11,045 (range: $5129-$20,751). The largest median operating cost category was personnel ($10,307; range: $4122-$19,794), with the highest personnel costs attributable to the provision of in-person program services. Monthly (non-zero) cost ranges for other categories were medications ($17-$573), materials ($6-$435), training ($96-$516), technology ($171-$2759), and equipment ($10-$620). Median cost-per-participant was $466 (range: $70-$2093) and cost-per-quit was $2688 (range: $330-$9628), with sites offering different combinations of program components, ranging from individually-delivered in-person counseling only to one program that offered all components. Site interviews provided context for understanding variations in program components and their cost implications. Among most centers that have progressed in tobacco treatment program implementation, cost-per-quit was modest relative to other prevention interventions. Although select centers have achieved similar average costs by offering program components of various levels of intensity, they have varied widely in program reach and effectiveness. Evaluating implementation costs of such programs alongside reach and effectiveness is necessary to provide decision makers in oncology settings with the important additional information needed to optimize resource allocation when establishing tobacco treatment programs.

Sections du résumé

BACKGROUND BACKGROUND
The Cancer Center Cessation Initiative (C3I) was launched in 2017 as a part of the NCI Cancer Moonshot program to assist NCI-designated cancer centers in developing tobacco treatment programs for oncology patients. Participating centers have implemented varied evidence-based programs that fit their institutional resources and needs, offering a wide range of services including in-person and telephone-based counseling, point of care, interactive voice response systems, referral to the quitline, text- and web-based services, and medications.
METHODS METHODS
We used a mixed methods comparative case study design to evaluate system-level implementation costs across 15 C3I-funded cancer centers that reported for at least one 6-month period between July 2018 and June 2020. We analyzed operating costs by resource category (e.g., personnel, medications) concurrently with transcripts from semi-structured key-informant interviews conducted during site visits. Personnel salary costs were estimated using Bureau of Labor Statistics wage data adjusted for area and occupation, and non-wage benefits. Qualitative findings provided additional information on intangible resources and contextual factors related to implementation costs.
RESULTS RESULTS
Median total monthly operating costs across funded centers were $11,045 (range: $5129-$20,751). The largest median operating cost category was personnel ($10,307; range: $4122-$19,794), with the highest personnel costs attributable to the provision of in-person program services. Monthly (non-zero) cost ranges for other categories were medications ($17-$573), materials ($6-$435), training ($96-$516), technology ($171-$2759), and equipment ($10-$620). Median cost-per-participant was $466 (range: $70-$2093) and cost-per-quit was $2688 (range: $330-$9628), with sites offering different combinations of program components, ranging from individually-delivered in-person counseling only to one program that offered all components. Site interviews provided context for understanding variations in program components and their cost implications.
CONCLUSIONS CONCLUSIONS
Among most centers that have progressed in tobacco treatment program implementation, cost-per-quit was modest relative to other prevention interventions. Although select centers have achieved similar average costs by offering program components of various levels of intensity, they have varied widely in program reach and effectiveness. Evaluating implementation costs of such programs alongside reach and effectiveness is necessary to provide decision makers in oncology settings with the important additional information needed to optimize resource allocation when establishing tobacco treatment programs.

Identifiants

pubmed: 33836840
doi: 10.1186/s43058-021-00144-7
pii: 10.1186/s43058-021-00144-7
pmc: PMC8033545
doi:

Types de publication

Journal Article

Langues

eng

Pagination

41

Subventions

Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NCI NIH HHS
ID : 17GZSK0031
Pays : United States

Références

BMJ. 2004 Apr 17;328(7445):947-9
pubmed: 15087348
Am J Prev Med. 2020 Oct;59(4):615-617
pubmed: 32446750
JAMA. 2020 Oct 13;324(14):1401-1403
pubmed: 33048141
N Engl J Med. 2019 Feb 7;380(6):512-515
pubmed: 30601710
Lung Cancer. 2005 Mar;47(3):351-9
pubmed: 15713518
Int J Environ Res Public Health. 2020 Mar 24;17(6):
pubmed: 32213994
J Clin Oncol. 2005 Sep 20;23(27):6516-23
pubmed: 16116148
Front Public Health. 2020 Jun 12;8:221
pubmed: 32596200
Nicotine Tob Res. 2019 Oct 26;21(11):1453-1461
pubmed: 29917118
JAMA Netw Open. 2019 Apr 5;2(4):e191703
pubmed: 30951159
Cancer Med. 2018 Sep;7(9):4765-4772
pubmed: 30019421
J Thorac Oncol. 2015 Jul;10(7):1014-9
pubmed: 26102442
Nicotine Tob Res. 2016 Dec;18(12):2216-2224
pubmed: 27613928
Nicotine Tob Res. 2013 Jan;15(1):52-8
pubmed: 22499079
Implement Sci. 2014 Apr 05;9(1):43
pubmed: 24708893
Int J Environ Res Public Health. 2020 Jun 30;17(13):
pubmed: 32629953
Prev Med. 2021 May;146:106469
pubmed: 33639182
JAMA. 1997 Dec 3;278(21):1759-66
pubmed: 9388153
PLoS One. 2019 Dec 9;14(12):e0226110
pubmed: 31815948
JAMA Netw Open. 2019 Sep 4;2(9):e1912264
pubmed: 31560380
Int J Environ Res Public Health. 2020 May 06;17(9):
pubmed: 32384731
J Natl Compr Canc Netw. 2016 Nov;14(11):1430-1468
pubmed: 27799513
Cancer Prev Res (Phila). 2019 Nov;12(11):735-740
pubmed: 31481540
Head Neck. 2002 Dec;24(12):1031-7
pubmed: 12454940
Clin Cancer Res. 2016 Apr 15;22(8):1907-13
pubmed: 26888828
Lancet Oncol. 2014 Nov;15(12):e568-80
pubmed: 25439699
Pract Radiat Oncol. 2016 Jan-Feb;6(1):12-8
pubmed: 26598909
Ann Behav Med. 2009 Apr;37(2):218-27
pubmed: 19291342
J Thorac Oncol. 2009 Apr;4(4):499-504
pubmed: 19204575
J Clin Oncol. 2015 Mar 10;33(8):885-93
pubmed: 25646196
Nicotine Tob Res. 2016 Aug;18(8):1684-96
pubmed: 26783291
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Cancer. 2014 Jul 1;120(13):1914-6
pubmed: 24687615
J Oncol Pract. 2013 Sep;9(5):258-62
pubmed: 23943904
J Clin Oncol. 2016 Apr 20;34(12):1315-22
pubmed: 26811527
Implement Sci. 2019 Jan 11;14(1):2
pubmed: 30635001
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):3-9
pubmed: 24420982
BMJ. 2013 Mar 25;346:f1049
pubmed: 23529982
Radiat Oncol. 2013 Jan 29;8:21
pubmed: 23360540
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2404-11
pubmed: 24319070
Transl Lung Cancer Res. 2015 Aug;4(4):339-52
pubmed: 26380175
Lung Cancer. 2010 Feb;67(2):221-6
pubmed: 19497635
Adm Policy Ment Health. 2011 Jan;38(1):44-53
pubmed: 20967495
J Thorac Oncol. 2013 May;8(5):543-8
pubmed: 23529191

Auteurs

Ramzi G Salloum (RG)

Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA. rsalloum@ufl.edu.

Heather D'Angelo (H)

University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Ryan P Theis (RP)

Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA.

Betsy Rolland (B)

University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
University of Wisconsin Institute for Clinical and Translational Research, Madison, WI, USA.

Sarah Hohl (S)

University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Danielle Pauk (D)

University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Jennifer H LeLaurin (JH)

Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA.

Yasmin Asvat (Y)

Rush University Medical Center and Rush Cancer Center, Chicago, IL, USA.

Li-Shiun Chen (LS)

Washington University Siteman Cancer Center, St Louis, MO, USA.

Andrew T Day (AT)

University of Texas Southwestern Medical Center, Dallas, TX, USA.

Adam O Goldstein (AO)

University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.

Brian Hitsman (B)

Northwestern University Feinberg School of Medicine and Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

Deborah Hudson (D)

Indiana University Simon Cancer Center, Indianapolis, IN, USA.

Andrea C King (AC)

University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.

Cho Y Lam (CY)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Katie Lenhoff (K)

Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon, NH, USA.

Arnold H Levinson (AH)

University of Colorado Comprehensive Cancer Center, Aurora, CO, USA.

Judith Prochaska (J)

Stanford Cancer Institute, Stanford University, Stanford, CA, USA.

Fabrice Smieliauskas (F)

Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.

Kathryn Taylor (K)

Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, USA.

Janet Thomas (J)

University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.

Hilary Tindle (H)

Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Elisa Tong (E)

University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Justin S White (JS)

Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA.

W Bruce Vogel (WB)

Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA.

Graham W Warren (GW)

Medical University of South Carolina Hollings Cancer Center, Charleston, SC, USA.

Michael Fiore (M)

University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
University of Wisconsin Institute for Clinical and Translational Research, Madison, WI, USA.
University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, USA.

Classifications MeSH